Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage

Stroke

Volumn 40, Issue 11, 2009, Pages 3631-3634

  Tsivgoulis, Georgios ^a,b,c   Frey, James L ^a   Flaster, Murray ^a   Sharma, Vijay K ^b,d   Lao, Annabelle Y ^a   Hoover, Steven L ^a   Liu, Wei ^a   Stamboulis, Elefterios ^e   Alexandrov, Anne W ^a,b   Malkoff, Marc D ^a   Alexandrov, Andrei V ^a,b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Blood pressure; Intracranial hemorrhage; Outcome; Stroke; Thrombolysis; TPA

Indexed keywords

LABETALOL; NICARDIPINE; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CONTINUOUS INFUSION; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CEREBRAL HEMORRHAGE; COHORT STUDIES; FEMALE; HUMANS; INTRACRANIAL HYPERTENSION; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 70350524024     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.564096     Document Type: Article

References (13)

1. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, Torner JC, Marler JR. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992;23:641-645.
2. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
4. Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ. Stroke Council of the American Stroke Association Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003;34:1056-1083.
5. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. IST Collaborative Group. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke. 2002;33:1315-1320.
6. Hill MD, Buchan AM. Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005; 172:1307-1312.
7. Lindsberg PJ, Soinne L, Roine RO, Salonen O, Tatlisumak T, Kallela M, Häppölä O, Tiainen M, Haapaniemi E, Kuisma M, Kaste M. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke. 2003;34:1443-1449.
8. Frey JL, Jahnke HK, Bulfinch EW. Differences in stroke between white, Hispanic, and Native American patients: the Barrow Neurological Institute stroke database. Stroke. 1998;29:29-33.
9. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recom-binant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32:438-441.
10. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, Levine SR. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105:1679-1685.
11. Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, Lees KR, Toni D. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis. Retrospective analysis from safe implementation of thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009;40:2442-2449.
12. Tsivgoulis G, Saqqur M, Sharma VK, Lao AY, Hill MD, Alexandrov AV. CLOTBUST Investigators. Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke. Stroke. 2007;38:961-966.
13. Saqqur M, Tsivgoulis G, Molina CA, Demchuk AM, Siddiqui M, Alvarez-Sabín J, Uchino K, Calleja S, Alexandrov AV. CLOTBUST Investigators. Symptomatic intracerebral hemorrhage and recanaliza-tion after IV rt-PA: a multicenter study. Neurology. 2008;71:1304-1312.